

General information about company	
Scrip code*	543064
NSE Symbol*	COHANCE
MSEI Symbol*	NOTLISTED
ISIN*	INE03QK01018
Name of company	Cohance Lifesciences Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	12-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	27-09-2025
Description of presentation currency	INR
Level of rounding	Crores
Reporting Type	Half Yearly
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	12-11-2025 17:30
End date and time of board meeting	12-11-2025 18:10

Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives	NA

appointed for a fixed tenure.	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	03-02-2025
Indicate Company website link for updated RPT policy of the Company	https://www.suvenpharm.com/pdf/Investors/corporategovernance/policies/Policy%20on%20materiality%20of%20RPT%20and%20dealing%20with%20RPT.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on	No Not Applicable

Loans and Debt Securities is applicable to the entity?	
--	--

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-04-2025	01-04-2025	
Date of end of reporting period		30-09-2025	30-09-2025	
Whether results are audited or unaudited		Unaudited	Unaudited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	981.37	981.37	
	Other income	39.4	39.4	
	Total income	1020.77	1020.77	
2	Expenses			
(a)	Cost of materials consumed	363.35	363.35	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-78.98	-78.98	
(d)	Employee benefit expense	198.53	198.53	
(e)	Finance costs	12.04	12.04	
(f)	Depreciation, depletion and amortisation expense	62.56	62.56	
(g)	Other Expenses			
1	Other Expenses	263.41	263.41	
	Total other expenses	263.41	263.41	
	Total expenses	820.91	820.91	
3	Total profit before exceptional items and tax	199.86	199.86	
4	Exceptional items	-8.1	-8.1	
5	Total profit before tax	191.76	191.76	
6	Tax expense			
7	Current tax	44.36	44.36	
8	Deferred tax	0.54	0.54	
9	Total tax expenses	44.9	44.9	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations	146.86	146.86	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	Net profit (loss) from discontinued operation after tax	0	0	

15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	146.86	146.86	
17	<u>Other comprehensive income net of taxes</u>	-6.42	-6.42	
18	Total Comprehensive Income for the period	140.44	140.44	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	38.26	38.26	
	Face value of equity share capital	1	1	
22	Reserves excluding revaluation reserve			
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	3.84	3.84	
	Diluted earnings (loss) per share from continuing operations	3.83	3.83	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	3.84	3.84	
	Diluted earnings (loss) per share from continuing and discontinued operations	3.83	3.83	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Text Block	
Textual Information(4)	Since the characters in the notes exceed the set limit, it is requested to refer to the detailed notes in PDF result as uploaded on the Stock Exchanges.

Statement of Asset and Liabilities		
Particulars		Half Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		30-09-2025
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	1397.52
	Capital work-in-progress	334.98
	Investment property	0
	Goodwill	644.11
	Other intangible assets	37.22
	Intangible assets under development	3.74
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets	
	Non-current investments	925.26
	Trade receivables, non-current	0
	Loans, non-current	0.91
	Other non-current financial assets	26.63
	Total non-current financial assets	952.8
	Deferred tax assets (net)	
	Other non-current assets	59.73
	Total non-current assets	3430.1
2	Current assets	
	Inventories	578.94
	Current financial asset	
	Current investments	298.27
	Trade receivables, current	528.6
	Cash and cash equivalents	36.97
	Bank balance other than cash and cash equivalents	14.8
	Loans, current	13.79
	Other current financial assets	1.49
	Total current financial assets	893.92
	Current tax assets (net)	13.61
	Other current assets	179.93

	Total current assets	1666.4
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	5096.5
	Total current assets	1666.4
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	5096.5
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	38.26
	Other equity	4370.94
	Total equity attributable to owners of parent	4409.2
	Non controlling interest	
	Total equity	4409.2
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	72.86
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	44.36
	Total non-current financial liabilities	117.22
	Provisions, non-current	0
	Deferred tax liabilities (net)	32.19
	Deferred government grants, Non-current	
	Other non-current liabilities	
	Total non-current liabilities	149.41
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	111.75
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	10.72
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	279.11
	Total Trade payable	289.83
	Other current financial liabilities	65.87

	Total current financial liabilities	467.45
	Other current liabilities	23.69
	Provisions, current	39.42
	Current tax liabilities (Net)	7.33
	Deferred government grants, Current	
	Total current liabilities	537.89
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	687.3
	Total equity and liabilities	5096.5
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block	
Textual Information(1)	Since the characters in the notes exceed the set limit, it is requested to refer to the detailed notes in PDF result as uploaded on the Stock Exchanges.

Other Comprehensive Income			
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-09-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Items that will not be reclassified to profit or loss	0.06	0.06
	Total Amount of items that will not be reclassified to profit and loss	0.06	0.06
2	Income tax relating to items that will not be reclassified to profit or loss	0.02	0.02
3	Amount of items that will be reclassified to profit and loss		
1	Items that will be reclassified to profit or loss	-8.64	-8.64
	Total Amount of items that will be reclassified to profit and loss	-8.64	-8.64
4	Income tax relating to items that will be reclassified to profit or loss	-2.18	-2.18
5	Total Other comprehensive income	-6.42	-6.42

Cash flow statement, indirect		
Particulars		Half Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		30-09-2025
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	191.76
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	10.64
	Adjustments for decrease (increase) in inventories	-124.02
	Adjustments for decrease (increase) in trade receivables, current	212.32
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	13.55
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	30.09
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-35.53
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	64.57
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	-6.93
	Adjustments for dividend income	0
	Adjustments for interest income	1.16
	Adjustments for share-based payments	5.97
	Adjustments for fair value losses (gains)	-10.87
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0

	Other adjustments to reconcile profit (loss)	-14.45
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	144.18
	Net cash flows from (used in) operations	335.94
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	57.99
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	277.95
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	66.56
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	1.5
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0

	Dividends received	0
	Interest received	0.53
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-104.81
	Net cash flows from (used in) investing activities	-172.34
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	32.43
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	65.62
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	7.94
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-58.01
	Net cash flows from (used in) financing activities	-99.14
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	6.47
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	-0.11
	Net increase (decrease) in cash and cash equivalents	6.36
	Cash and cash equivalents cash flow statement at beginning of period	30.61
	Cash and cash equivalents cash flow statement at end of period	36.97

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)																									
														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes	
1	Cohance Lifesciences Limited		Sapala Organics Private Limited		Subsidiary	Any other transaction	Consultany charges		Approved			0.19	0	0.08											
2	Cohance Lifesciences Limited		Sapala Organics Private Limited		Subsidiary	Purchase of goods or services			Approved			0.01	0	0.01											
3	Sapala Organics Private Limited		Rasayan Inc		Shareholder	Sale of goods or services			Approved			0.21	0	0											
4	Sapala Organics Private Limited		Rasayan Inc		Shareholder	Any other transaction	Business Promotion expense		Approved			0.44	0.14	0.11											
5	Sapala Organics Private Limited		Sapala Co., Ltd		Enterprise over which KMP have significant influence	Sale of goods or services			Approved	0.29	12-11-2025	5.29	3.38	4.39											
6	Sapala Organics Private Limited		Sapala Co., Ltd		Enterprise over which KMP have significant influence	Any other transaction	Business Promotion expense		Approved			0.08	0	0											
7	Cohance Lifesciences Limited		NJ BIO INC		Subsidiary	Any other transaction	Commission on Corporate Guarantee		Approved			0.42	0	0.42											
8	NJ BIO INC		NJBIO INDIA PRIVATE LIMITED		Wholly Owned Subsidiary	Purchase of goods or services			Approved			6.04	5.82	5.99											
9	NJ BIO INC		Aruka Bio INC		Associate	Sale of goods or services			Approved			12.7	7.93	25.1											
Total value of transaction during the reporting period												25.38													